[1]安妮,杨俊兰.消 疒徵祛积方联合化疗对晚期乳腺癌患者血清CEA、CA125、CA153和CA19-9含量及临床疗效的影响[J].西部中医药,2013,26(03):7-9.
 AN Ni,YANG Junlan.Effects of XiaoZhen QuJiFang and Chemotherapy on Clinical Efficacy and Contents of Serum CEA, CA125, CA153 and CA19-9 of Patients with Mammary Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(03):7-9.
点击复制

消 疒徵祛积方联合化疗对晚期乳腺癌患者血清CEA、CA125、CA153和CA19-9含量及临床疗效的影响
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
26
期数:
2013年03期
页码:
7-9
栏目:
论著·临床论著
出版日期:
2013-03-15

文章信息/Info

Title:
Effects of XiaoZhen QuJiFang and Chemotherapy on Clinical Efficacy and Contents of Serum CEA, CA125, CA153 and CA19-9 of Patients with Mammary Cancer at Advanced Stage
文章编号:
1004-6852(2013)03-0007-03
作者:
安妮12杨俊兰1
1 解放军总医院肿瘤科,北京 100853;2 总政莲花池干休所卫生所
Author(s):
AN Ni1 2 YANG Junlan1
1 Oncology of Department in Chinese PLA General Hospital, Beijing 100853, China; 2 Health-center of LianHuaChi Cadres Sanitorium to The General Political Department of PLA
关键词:
乳腺癌消癥祛积方化疗
Keywords:
mammary cancer XiaoZhen QuJiFang chemotherapy
分类号:
R737.9
文献标志码:
A
摘要:
目的:观察消 祛积方联合化疗对晚期乳腺癌患者血清癌胚抗原(CEA),卵巢癌相关抗原(CA125),胰腺、乳腺癌相关抗原(CA153),肠癌相关抗原(CA19-9)含量及临床疗效的影响。方法:将 120 例乳腺癌患者随机分为观察组、对照组各 60 例。2 组均给予相同的化疗方案:吉西他滨,1 000 mg/m2,静脉滴注;分别于第 1 和 8 天起;顺铂 25 mg/m2,静脉滴注,3 天。观察组同时给予消 祛积方,1 剂 /d,水煎分服。2 组均以 3 周为1 个周期,常规治疗 4 个周期。结果:CEA、CA125、CAl53 和 CA19-9 等肿瘤标记物 2 组治疗后均有明显改善(P<0.05);且观察组改善较对照组明显(P<0.05)。2 组生理机能、躯体疾病、一般健康状况、精力、精神健康等生活质量评价治疗后较治疗前明显改善(P<0.05);观察组较对照改善明显(P<0.05)。总有效率观察组为91.67%,对照组为 63.33%,2 组比较差异有统计学意义(P<0.05)。2 组均出现了白细胞减少、血小板减少、贫血、恶心呕吐、肝功能异常、肾功能异常、周围神经毒性、脱发等毒副反应,但对照组毒副反应发生率较观察组高(P<0.05)。结论:消 祛积方联合化疗治疗乳腺癌可改善 CEA、CA125、CAl53 和 CA19-9 等肿瘤标记物,改善患者生活质量,提高临床疗效,降低毒副反应。
Abstract:
Objective: To verify the effects of XiaoZhen QuJiFang combined with chemotherapy on clinical efficacy and contents of serum CEA, CA125, CA19-9 and CA153 in patients with mammary cancer at advanced stage. Method: All 120 patients were randomized into the observation group and the control group; both groups received the same chemotherapy: gemcitabine, 1 000 mg/m2, intravenous dripping; began at the first and eighth day;cis-platinum complexes 25 mg/m2, intravenous dripping, for three days. The observation group took XiaoZhen QuJiFang, one dose each day, decocted with water. Three weeks were one course of treatment for both groups and they were treated for four courses of treatment. Result: Both groups were improved after treating in tumor markers including CEA, CA125, CA153 and CA19-9 (P< 0.05); and the improvement of the observation group was more significant than that of the control group (P< 0.05). Both groups were improved more greatly after treating than before treating in assessment of life quality such as physiological function, diseases, general health, energy and mental health (P< 0.05); the improvements of the observation group were more significant then the control group after treating (P< 0.05). Total effective rate of the observation group was 91.67%, higher than 63.33% of the control group with difference and it showed statistical meaning (P< 0.05). Both groups manifested adverse reactions such as leukocytes decrease, platelet decrease, anemia, nausea, vomiting, abnormality of liver function and renal function,peripheral neurotoxicity and alopecia. Incidence of adverse reactions in the control group was higher than that of the observation groups (P< 0.05). Conclusion: XiaoZhen QuJiFang combined with chemotherapy in treating mammary cancer could improve tumor markers including CEA, CA125, CA153 and CA19-9, life quality of the patients, raise clinical efficacy and decrease toxic reactions.

参考文献/References:

[1] 周际昌.实用肿瘤内科学[M].北京:人民卫生出版社,2003:517. [2] 汤献猷.现代肿瘤学[M].上海:复旦大学出版社,2003:820. [3] 苗晓,周勤.血清 CA125 在卵巢良恶性肿瘤诊断及监控的临床分析[J].中外医疗,2008,27(31):139-140. [4] 唐黎,申剑,武明花.卡培他滨联合长春瑞滨治疗复发转移性乳腺癌的临床观察[J].临床肿瘤学杂志,2010,15(1):67-69. [5] 周庆华,吴迎,蔡中瑞,等.新辅助化疗对乳腺癌患者 ER、PR、C-erbB-2、Ki-67 表达的影响[J].中国癌症杂志,2008,18(2):139-141. [8] 许隽颖,刘超英,李江,等.肿瘤标志物 CEA、CA15-3 和 CA125在乳腺癌化疗疗效评估中的价值[J].放射免疫学杂志,2009,22(2):160-162. [7] 熊良庚.扶正消积方联合化疗对晚期乳腺癌患者生活质量及血清肿瘤标志物的影响[J].云南中医中药杂志,2012,33(4):14-15. [8] 蔡鹏,王建国,杨士勇,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].中国肿瘤临床与康复,2007,14(2):142-143. [9] 陈武进,齐彦,皇甫真萍,等.康艾注射液对晚期胃肠癌患者生活质量的影响[J].甘肃中医,2006,19(9):21-22.

相似文献/References:

[1]刘琛,吴黎雅,赵红佳,等.人参养荣汤干预乳腺癌新辅助化疗所致气血两虚证的临床研究[J].西部中医药,2011,24(11):3.
[2]王斌,王艳杰,梁贵文,等.乳积方防治乳腺癌患者术后复发转移的临床研究*[J].西部中医药,2013,26(08):101.
 WANG Bin,WANG Yanjie,LIANG Guiwen,et al.Clinical Study on RuJiFang to Prevent Postoperative Recurrence and Metastasis of Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(03):101.
[3]李树建.扶正祛积汤联合CEF化疗方案治疗晚期乳腺癌40例临床研究[J].西部中医药,2013,26(09):1.
 LI Shujian.Clinical Study on FuZheng QuJiTang Combined with CEF Chemotherapy in Treating 40 Patients Suffering from Advanced Mammary Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(03):1.
[4]侯俊明,江静.疏肝解郁法联合化疗治疗乳腺癌临床疗效分析[J].西部中医药,2014,27(09):1.
[5]王丽,何丽娟,朱玉芹.循证护理对乳腺癌化疗患者自尊水平和应对方式的影响[J].西部中医药,2014,27(11):134.
[6]朱慧华.纽曼护理对乳腺癌手术患者心理健康和生活质量的影响[J].西部中医药,2014,27(12):105.
[7]谷雨,华海清△.中医辨证分型与乳腺癌预后的相关性研究[J].西部中医药,2015,28(04):85.
[8]王泽芬.集束护理干预策略对乳腺癌保乳术后放化疗患者的影响[J].西部中医药,2015,28(04):137.
[9]张晓华,张晓岚△,梁玉荣,等.综合心理干预对乳腺癌化疗患者医学应对方式及生命质量的影响[J].西部中医药,2015,28(07):123.
[10]马云飞,孙旭,杨永,等.乳腺癌的中医证型及用药规律研究[J].西部中医药,2017,30(01):46.
 MA Yunfei,SUN Xu,YANG Yong,et al.Study on TCM Syndrome and Medication Rule of Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2017,30(03):46.

备注/Memo

备注/Memo:
收稿日期:2012-10-10 作者简介:安妮(1977—),女,主治医师。研究方向:肿瘤疾病的诊治。
更新日期/Last Update: 2013-03-15